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MSY2RNA is thought to be essential to undergo the maternal-to-embryonic transition.
Messenger RNA is extremely stable during oocyte growth in mouse and MSY2, an abundant germ cell-
speciﬁc RNA-binding protein, likely serves as a mediator of global mRNA stability. Oocyte maturation,
however, triggers an abrupt transition in which most mRNAs are signiﬁcantly degraded. We report that
CDC2A (CDK1)-mediated phosphorylation of MSY2 triggers this transition. Injecting Cdc2a mRNA, which
activates CDC2A, overcomes milrinone-mediated inhibition of oocyte maturation, induces MSY2 phosphor-
ylation and the maturation-associated degradation of mRNAs. Inhibiting CDC2A following its activation with
roscovitine inhibits MSY2 phosphorylation and prevents mRNA degradation. Expressing non-phosphor-
ylatable dominant-negative forms of MSY2 inhibits the maturation-associated decrease in mRNAs, whereas
expressing constitutively active forms induces mRNA degradation in the absence of maturation and
phosphorylation of endogenous MSY2. A positive-feedback loop of CDK1-mediated phosphorylation of MSY2
that leads to degradation ofMsy2mRNA that in turn leads to a decrease in MSY2 protein may ensure that the
transition is irreversible.
© 2008 Elsevier Inc. All rights reserved.IntroductionSomatic cells usually divide after doubling their volume, whereas
oocytes grow in the absence of cell division; in mouse, oocyte volume
increases N200-fold during the growth phase (Schultz and Wassar-
man, 1977). The accumulated organelles and macromolecules con-
stitute the maternal capital that is inherited by the embryo and
partitioned to the blastomeres that form during a series of reductive
cleavage divisions prior to implantation. Following implantation there
is an increase in mass. During the growth phase that takes ~3 weeks,
oocyte mRNA is very stable with a half-life of ~12 days (Bachvarova
and DeLeon, 1980; Brower et al., 1981). This stability presumably is a
major factor that permits mRNA accumulation, especially because a
progressive decrease in transcription initiates aroundmid-growth, the
time of antrum formation (Moore, 1975; Moore and Lintern-Moore,
1978), and results in a fully-grown oocyte that is essentially
transcriptionally quiescent.
In females, MSY2 (mouse speciﬁc Y-box protein 2), which is a germ
cell-speciﬁc RNA-binding protein, is implicated in mRNA stability (Yu
et al., 2004, 2001, 2002, 2003). MSY2 belongs to a large protein family
that is conserved from bacteria to humans (Gu et al., 1998; Jiang et al.,iversity of Pennsylvania, 433
USA.
tz).
l rights reserved.1997; Salvetti et al., 1998; Swamynathan et al., 1998; Tafuri andWolffe,
1990; Tekur et al., 1999; Thieringer et al., 1997). Y-box proteins
typically consist of a highly divergent N-terminus, a conserved cold-
shock domain, and a C-terminal tail domain; the cold-shock domain
contains ~67–80 amino acids, which are 43% identical from bacteria to
humans (Sommerville and Ladomery,1996;Wolffe, 1994;Wolffe et al.,
1992). This domain contains the RNP1 and RNP2 RNA-binding motifs
(Schindelin et al., 1994).
In oocytes N70% of MSY2 remains in a Triton X-100 insoluble
fraction and its RNA-binding activity is required for this association
(Yu et al., 2003). The predominant localization of MSY2 in this
insoluble fractionmay contribute tomRNA stability during the growth
phase because MSY2-associated mRNAs may be protected from
degradation. Consistent with this hypothesis is that a 60–70% decrease
in the amount of MSY2 using a transgenic RNAi approach results in a
20% decrease in the amount of total mRNA (Yu et al., 2004). Moreover,
the developmental competence of these transgenic oocytes is
compromised resulting in a marked sub-fertility (Yu et al., 2004)
and female mice lackingMsy2 are infertile (Yang et al., 2005b). In male
germ cells absence of MSY2 due to gene targeting leads to mRNA
instability MSY2 (Yang et al., 2007) but MSY2 is soluble following
Triton X-100 treatment (Yu et al., 2003).
There is a growing consensus that degradation of maternal mRNA
is essential to undergo successfully the maternal-to-zygotic transition
(DeRenzo and Seydoux, 2004; Stitzel and Seydoux, 2007). This
transition entails transforming a highly differentiated oocyte—the
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expresses oocyte-speciﬁc genes (e.g., the zona pellucida genes) and
whose cytoplasm is capable of reprogramming a transplanted somatic
cell nucleus—to totipotent blastomeres by the 2-cell stage. In contrast
to the marked stability of mRNA during oocyte growth, oocyte
maturation triggers a substantial decrease in mRNA (Schultz, 1993; Su
et al., 2007). The molecular basis underlying this dramatic transition
in mRNA stability, however, is not known.
MSY2 is phosphorylated during oocyte maturation following
germinal vesicle breakdown (GVBD), such that virtually all MSY2 is
phosphorylated in the metaphase II-arrested egg (Yu et al., 2001);
fertilization triggers the conversion to the dephosphorylated form and
by the 2-cell stage MSY2 is essentially absent (Yu et al., 2001). The
protein kinase(s) responsible for this phosphorylation—either directly
or indirectly—is not known nor is the effect of phosphorylation of
MSY2 on its function. We report here that CDC2A mediates, likely
directly, MSY2 phosphorylation and that this phosphorylation triggers
degradation of endogenous mRNAs.
Materials and methods
Oocyte collection and culture
Msy2-knock-down (KD) mice have been described (Yu et al., 2004).
Unless otherwise stated all experiments were conducted using fully-
grown GV-intact oocytes that were harvested from CF1, eCG-primed,
6-week-old females and completely freed of attached cumulus cells
via repeated mouth-pipetting. Oocytes were either allowed to mature
in vitro in CZB medium (Chatot et al., 1989) or incubated in the
presence of 2.5 μMmilrinone (Sigma) to inhibit GVBD (Wiersma et al.,
1998) for either 6 h or 16–18 h.
Growingmeiotically incompetent oocytes were harvested from 13-
day-old CF1 female mice (Brower et al., 1981). The small fraction of
oocytes that underwent spontaneous GVBD during the ﬁrst 3 h of
incubationwas discarded and the remaining oocytes were considered
as GVBD-incompetent oocytes. All animal experiments were approved
by the Institutional Animal Use and Care Committee and were
consistent with National Institutes of Health guidelines.
Protein kinase assays
Oocytes were matured in vitro for the different times from 0 to
120 min or overnight, and CDC2A and mitogen-activated protein
kinase (MAPK) activities were measured using histone H1 and myelin
basic protein (MBP) as substrates, respectively, as previously described
(Svoboda et al., 2000).
Triton X-100 treatment, and salt and RNase treatments
The Triton X-100 insoluble fraction was generated as previously
described (Yu et al., 2003). Brieﬂy, at least 20 oocytes were treated
with 0.1% Triton X-100 containing 100 mM KCl, 5 mM MgCl2, 3 mM
EGTA, 20 mM Hepes, pH 6.8, and 1% BSA (intracellular buffer, ICB) for
10 min at room temperature followed by three washes with ICB.
The salt-sensitivity of MSY2 retention in the insoluble preparation
was determined by incubating at least 20 oocytes or MII eggs in 0.1%
Triton X-100 containing 100 mM to 1000 mM KCl in ICB for 10 min at
room temperature. The fraction was then washed three times in ICB.
The RNase-sensitivity of MSY2 retention and susceptibility of
endogenous mRNA to degradation in the insoluble preparation was
determined by subjecting oocytes or MII eggs to RNase treatment at
different concentrations (1–100 ng/ml in ICB) for 15 min at room
temperature following permeabilization with 0.1% Triton X-100.
To quantify the amount of MSY2, the material was transferred to
2X SDS-PAGE sample buffer prior to immunoblot analysis. To quantify
the amount of speciﬁc mRNAs, the material was transferred to lysisbuffer (Absolutely RNA Microprep Kit, Stratagene, La Jolla, CA) and
stored at −80 °C prior to Real-Time PCR (qRT-PCR) analysis.
Treatment of oocytes and MII eggs with a CDC2A or MAP kinase inhibitor
Oocytes were monitored for GVBD and those that had undergone
GVBD within 5 min were rapidly transferred to CZB containing 60 μM
roscovitine (Biomol, Plymouth Meeting, PA), a CDC2A inhibitor, or
10 μM U0126 (Biomol), a MAP kinase (MEK) inhibitor, and cultured
without an oil overlay at 37 °C in an atmosphere of 5% CO2 in air for 6 h
(corresponding to the MI stage) or for 16–18 h when they reached MII
stage. MII eggs that matured in vitro in inhibitor-free CZB were
incubated with roscovitine or U0126 for 3 h.
DNA constructs and site-directed mutagenesis
Plasmids pCdc2 (de Vantéry et al., 1997) containing the entire
coding region of mouse Cdc2a cDNA and p18.2 (Chapman and
Wolgemuth, 1992) containing mouse cyclin B1 (Ccnb1) cDNA were
the generous gift of D.J. Wolgemuth (Columbia University). Construct
MSY2-pET-28a(+) encoding MSY2 protein bearing a His tag at the
amino-terminus has been described (Yu et al., 2003). Construct
MSY2IR (hairpin)-pXT7 used in RNAi approach and a construct
encoding wild-type Msy2 (MSY2-EGFP-pXT7) have been described
(Yu et al., 2004). All Msy2 constructs had an Egfp tag at the carboxyl
terminus to monitor protein expression. Threonines at the potential
CDK1 phosphorylation sites [(S/T)P] in wild-type Msy2 were mutated
to alanine (to produce putative dominant-negative MSY2) or aspartic
acid (to produce putative constitutively active MSY2) by site-directed
mutagenesis using the single-stranded Phusion mutagenesis protocol
(BioLabs, Ipswich, MA). The following mouse Msy2 mutants were
generated: T58A, T67A, T78A, T58/67/78A, T58D, T67D, and T58/67D.
All expression constructs were veriﬁed by DNA sequencing.
mRNA preparation and microinjection
To prepare sense transcripts, pCdc2 was linearized with XbaI and
p18.2 was linearized with XhoI as described (de Vantéry et al., 1997).
Polyadenylated, capped Cdc2a mRNA was obtained using mMESSAGE
mMACHINE Ultra T7 Kit (Ambion, Austin, TX). In vitro transcription of
Ccnb1mRNAwas performed using the mMESSAGE mMACHINE T3 Kit
and Poly(A) Tailing Kit (Ambion). Constructs MSY2IR (hairpin)-pXT7,
MSY2-EGFP-pXT7, and all phosphorylation site-mutated Msy2 con-
structs were linearized with SacI and in vitro transcriptionwas carried
out using the mMESSAGE mMACHINE T7 kit (Ambion). mRNAs from
pCdc2 and p18.2 were resuspended at a concentration of 1 μg/μl, and
all other mRNAs were resuspended at a concentration of 2 μg/μl in TE
buffer, and stored at −80 °C prior to use for microinjection.
In the Cdc2a induction experiment, fully-grown oocytes were
microinjected with 5–10 pl of Cdc2a mRNA and then incubated in
CZB supplemented with 0.7 μM milrinone, which we determined
was a minimal concentration required to inhibit GVBD. We selected
this minimal concentration in order to maximize the ability of the
injected oocytes to overcome the milrinone block of GVBD. Under
these conditions we observed that 60–70% of Cdc2a mRNA-injected
oocytes underwent GVBD. Oocytes that underwent GVBD within 1 h
following injection were then incubated for an additional 6 h or for
16–18 h before they were harvested and stored at −80 °C until used
for immunoblot or qRT-PCR analysis. Meiotically-incompetent
oocytes were injected with both Cdc2a and Ccnb1 mRNAs (0.5 μg/
μl of each) to induce GVBD. The oocytes were incubated in CZB for
18 h, and typically all the microinjected meiotically incompetent
oocytes underwent GVBD.
For the RNAi experiment, 5–10 pl of Msy2 dsRNA was micro-
injected to cytoplasm of fully-grown oocytes followed by 18 h
incubation in the presence of 2.5 μM milrinone. Oocytes were then
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When dominant-negative forms of Msy2 were used, oocytes were
injected with the appropriate mRNA as described above and then
incubated in CZB supplemented with 200 μM IBMX to inhibit
maturation for 24 h. The oocytes were divided in two groups in
which one group remained in IBMX-containing CZB for another 18 h,
whereas oocytes in the other group were washed, transferred to
IBMX-free CZB and then cultured for 18 h before they were harvested
and stored at −80 °C until used for immunoblot or qRT-PCR analysis.
When constitutively active forms of Msy2 were used, oocytes were
injected with the appropriate mRNA and incubated in CZB supple-
mented with 200 μM IBMX for 40 h before they were harvested and
stored at −80 °C until used for the immunoblot or qRT-PCR analysis.
Immunoblotting
Samples were separated in a 10% SDS-PAGE gel and transferred to
an Immobilon P membrane (Millipore, Bedford, MA) using semidry
transfer. Membranes were processed and developed, and the signal
quantiﬁed as previously described (Yu et al., 2003). The α-MSY2
antibody was used in 1:2000 dilution. Detection and quantiﬁcation of
signal was done as previously described (Yu et al., 2003).
qRT-PCR analysis
The mRNA levels of the panel of 20 randomly selected oocyte-
expressed geneswere quantiﬁed using qRT-PCR. Brieﬂy, total RNA from
80 to 100 oocytes or MII eggs was extracted using the Absolutely RNA
Microprep Kit (Stratagene, La Jolla, CA) including a DNase step to reduce
genomic DNA to undetectable levels. In addition, 230 μM sodium
acetate (pH 5.2) and 40 μg glycogen (Roche Applied Science,
Indianapolis, IN) as a carrier, were added prior to precipitation with
ice-cold ethanol. Equal amounts of human GAPDH mRNA (PE Applied
Biosystems, Foster City, CA) were added to each sample before RNA
extraction to normalize for RNA extraction and reverse transcription
efﬁciency. First-strand complimentary DNA was synthesized by prim-
ing with random hexamers using Superscript II reverse transcriptase
(Invitrogen, Carlsbad, CA) following the manufacturer's instructions.
One oocyte equivalent of the resulting cDNA was used for each
real-time qPCR reaction with a minimum of three replicates (from
independently collected oocytes per replicate). qPCR reactions were
performed with TaqMan PCR Master reagents and 7700 sequence
detector (PE Applied Biosystems, Foster City, CA). The corresponding
ABI TaqMan Assay-on-Demand probe/primer sets used were
Mm00613618_m1 (Rnf38), Mm00446044_m1 (Xrcc3), Mm00
448776_m1 (Smarcb1), Mm02527099_q1 (Hdac1), Mm00656735_q1
(Gapdh), Mm00724124_m1 (AW545966), Mm00457046_m1 (Tbpl1),Fig.1. Relative amounts of speciﬁc mRNAs in oocytes containing reduced amounts of MSY2. T
to that in non-transgenic oocytes. The data are expressed as mean±SEM, n=3. The insert sh
oocytes. All of the differences are signiﬁcant (pb0.001 except for Smarcb1 (pb0.01) and HdMm00516130_m1 (Khdrbs1), Mm00491841_q1 (Rbm8), Mm00
488528_m1 (Refbp1), Mm00485509_m1 (Rad51ap1), Mm00
456651_m1 (Eif1a), Mm00520817_m1 (Mlh3), Mm00432498_m1
(Chkl). The following custom TaqMan probe/primer sets were
designed for
Mos (probe 5′CCGAGCCAAACCCTC3′,
forward primer 5′GGGAACAGGTATGTCTGATGCA3′,
reverse primer 5′CACCGTGGTAAGTAAGTGGCTTTATACA3′),
MUERV-L (probe 5′CCAGGAAAAGAGCCAAGACCTGCTGAT 3′,
forward primer 5′GGAATGAAGGTATGGGTCAATCC3′,
reverse primer 5′CCTTCACCTTCAGCCAGCAC3′),
Tead2 (probe 5′CGTGCGGCAGATCTACGACAAATTCC3′,
forward primer 5′TGGAGCACCACCCCTAGAGAG3′,
reverse primer 5′CCTCGGTCATACAGCTCGCG3′),
Msy2 (probe 5′CACCTCCCTCCCTAGTCAGGCTGAGAA 3′,
forward primer 5′CATCCTTATTGTTCCGAGGCA3′,
reverse primer 5′GGAGGTATGAGCTGGCTGGTT3′),
Pou5f1 (probe 5′CATGAAAGCCCTGCAGAAGGAGCTAGAAC 3′,
forward primer 5′CAACTCCCGAGGAGTCCCA3′,
reverse primer 5′GCTTCAGCAGCTTGGCAAAC 3′),
IAP (probe 5′CAGTTAGACAGGCTCGCCG3′, forward primer
5′TGCTAATTTTACCTTGGTGCAGTTA3′, reverse primer
5′GTTTGCCAGTCAGCAGTTA3′).
qRT-PCR ampliﬁcation of human GAPDH was used as a control for
normalization and no signal was observed in the minus RT control
when assaying for Rnf38. Quantiﬁcation was performed using the
comparative CT method (ABI PRISM 7700 Sequence Detection System,
user bulletin #2). The datawere analyzed using Prism software (Graph
Pad Software Inc., San Diego, CA).
Statistical analyses
Student's t-test (paired analysis) was used to determine whether
differences were statistically signiﬁcant.Results
MSY2 is required for mRNA stability during oocyte growth
We previously proposed that MSY2 serves as a global regulator of
mRNA stability and reported that reducing the amount of MSY2
protein inmouse oocytes by 50–70% using a transgenic RNAi approachhe relative amount of each transcript was determined by qRT-PCR and expressed relative
ows an immunoblot demonstrating the reduced amount of MSY2 protein in transgenic
ac1 (pb0.05).
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RNA in fully-grown oocytes (Yu et al., 2004). To assess whether the
decrease in MSY2 results in a uniform or transcript-speciﬁc decrease
in the mRNA population, we assayed by qRT-PCR the relative
abundance of a variety of randomly selected transcripts in transgenic
oocytes (Fig. 1). In every instance, a decrease in transcript abundance
was observed, but the magnitude of the decrease, which ranged from
~20–80%, was variable; the decrease in Msy2 mRNA was due to
targeting endogenous Msy2 mRNA by transgenic RNAi. None of the
assayed transcripts were those that are unstable in fully-grown
oocytes (Puschendorf et al., 2006) and only two transcripts (Rbm8 and
Chk1) were previously shown to be selectively degraded during oocyte
maturation (Su et al., 2007).
CDC2A initiates MSY2 phosphorylation
We previously demonstrated that MSY2 is phosphorylated
following GVBD (Yu et al., 2001). During maturation there is a
dramatic increase in CDC2A activity that occurs concomitant with
GVBD followed by activation of MAPK within an hour (Verlhac et al.,
1994). Each of these kinases phosphorylates a S/T residue that is
followed by a P residue and MSY2 contains three such potential
phosphorylation sites. The Scansite algorithm (scansite.mit.edu)
identiﬁes T58, T67, and T78 as potential CDC2A phosphorylation
sites using a low stringency ﬁlter; only T58 is identiﬁed when using a
medium stringency ﬁlter. Examination of the time course of MSY2
phosphorylation and activation of CDC2A and MAPK revealed that
phosphorylation, detected by the appearance of species of slower
electrophoretic mobility, correlated with CDC2A activation and not
MAPK activation (Fig. 2A); the multiple electrophoretic forms likely
represent MSY2 that is phosphorylated at more than one site.
Consistent with CDC2A, and not MAPK, triggering either direct
phosphorylation of MSY2 (or indirectly by activating another protein
kinase) is (1) the MEK inhibitor U0126, which ultimately inhibits
MAPK (Phillips et al., 2002), did not prevent the maturation-
associated phosphorylation of MSY2, (2) treatment of oocytes that
just underwent GVBDwith the CDC2A inhibitor roscovitine (Phillips et
al., 2002) blocked MSY2 phosphorylation, and (3) treatment of
metaphase II-arrested eggs with roscovitine resulted in the conver-
sion of the phosphorylated to the non-phosphorylated form (Fig. 2B).Fig. 2. (A) Time course of MSY2 phosphorylation, and CDC2A and MAPK activation. The
upper panel is an immunoblot of MSY2 showing the appearance of forms of slower
electrophoretic mobility becoming more apparent following GVBD. The times from
transfer to inhibitor-free medium are indicated above each lane and GVBD occurs
between 60 and 75 min following transfer to inhibitor-free medium. The middle panel
is CDC2A activity as assessed by histone H1 phosphorylation and the lower panel is
MAPK activity as assessed by myelin basic protein phosphorylation. Duplicate samples
for each time point are shown. (B) Immunoblots demonstrating effect of roscovitine and
U0126 on MSY2 phosphorylation. GV, GV-intact oocyte; GVBD/R, roscovitine was added
immediately after GVBD and the samples prepared 3 h later; MII, MII egg; MII/R,
roscotivine added toMII eggs and the samples prepared 3 h later; GVBD/U, U0126 added
immediately after GVBD and the samples prepared 3 h later; MII/U, U0126 added to MII
eggs and the samples prepared 3 h later; MII, MII egg.In addition, dephosphorylation of MSY2 that occurs following egg
activation correlates with the decrease in CDC2A activity (Yu et al.,
2001), which occurs prior to the decrease in MAPK activity (Moos et
al., 1995).
MSY2 phosphorylation correlates with changes in solubility and
accessibility of endogenous mRNAs to exogenous RNase
The bulk of MSY2 is insoluble following Triton X-100 extraction,
but RNase treatment of these preparations liberates MSY2 to the
soluble fraction (Yu et al., 2003). Treating Triton X-100 preparations of
GV-intact oocytes with increasing concentrations of KCl or RNase
resulted in a concentration-dependent release from the insoluble
fraction (Fig. 3A and Table 1). Signiﬁcantly lower concentrations of KCl
or RNase were required to liberate phosphorylated MSY2 present in
MII eggs.
Consistent with the change in solubility properties of MSY2
associated with phosphorylation, the fraction of MSY2 in the insoluble
fraction in MII-arrested eggs is less than the fraction in GV-intact
oocytes (Fig. 3B). In addition, the bulk of mRNAs (typically N80%)
present in GV-intact oocytes were associated with the Triton X-100
insoluble material but following maturation and arrest at MII, the
fraction of mRNA present in this insoluble material was less (Fig. 3C).
Taken together, these results suggest thatMSY2 phosphorylation leads
to a coordinate movement from the insoluble to soluble fraction of
MSY2 and associated mRNA. Furthermore, these results suggest that
MSY2 phosphorylation leads to changes in its ability to interact
directly with mRNA or other proteins present in MSY2-containing
ribonucleoprotein particles (RNPs). Such biochemical changes could
make mRNAs present in MSY2-containing particles more susceptible
to the degradation machinery, either directly or by being released into
the soluble pool and hence made more accessible.
We had previously demonstrated that RNase treatment (50 μg/ml)
of TX-100 insoluble material present in oocytes resulted in total
degradation of most mRNAs and release of virtually all of the MSY2 to
the soluble fraction (Yu et al., 2003). Using conditions for RNase
treatment (1 ng/ml) that resulted in little release of MSY2 from the
insoluble fraction (Fig. 3A), we then assayed a battery of randomly
selected transcripts present in the insoluble fractions in GV-intact and
MII eggs and found that the transcripts were more readily digested in
eggs, where MSY2 is phosphorylated, than in oocytes, where the bulk
of MSY2 is not phosphorylated (Fig. 4). These results suggest theMSY2
phosphorylation leads to mRNAs present in MSY2-containing RNPs
being more susceptible to RNase.
MSY2 phosphorylation correlates with mRNA degradation during oocyte
maturation
Maturation initiates degradation of maternal mRNAs that persists
into the 2-cell stage, such that for many mRNAs greater than 90% of
the maternal transcript is degraded by this time (Schultz, 1993).
Transcripts that are common to the oocyte and embryo, e.g., actin, are
replaced by zygotic expression that is clearly evident by the 2-cell
stage (Latham et al., 1991; Hamatani et al., 2004; Wang et al., 2004;
Zeng et al., 2004; Zeng and Schultz, 2005). We monitored degradation
of the selected transcripts by measuring the relative amount of each
transcript at MI and MII compared to that in the GV-intact oocyte (Fig.
5A). These experiments demonstrated that each mRNA was degraded
during maturation, but the kinetics and relative stability varied for
each mRNA. For example, some mRNAs show little degradation by MI
(Rnf38), whereas others exhibit signiﬁcant degradation by this time
(Eif1a). Most mRNAs displayed a further decrease between MI and MII
such that by MII the relative amount of the transcript ranged between
~80% (Mos) to ~10% (Chk1) of that present in the GV-intact oocyte. Of
note is that repetitive sequences, e.g., IAP, seemed most susceptible to
degradation, which is consistent with a previous study that noted
Table 1
Quantiﬁcation of amount of MSY2 present in insoluble fraction following either KCl or
RNase treatment
Treatment
KCl [M] RNase [ng/ml]
0.2 0.4 0.6 1 10 100
GV 80±6 51±10 17±3 84±6 60±10 10±1
MII 46±10 33±8 4±1 43±8 17±2 3±1
The data are relative to extracted but untreated oocytes orMII eggs and are expressed as
mean±SEM (n=3). Note that extracted but untreated cells are exposed to M KCl, which
is present in the extraction buffer.
Fig. 3. Effect of MSY2 phosphorylation on MSY2 and mRNA solubility. (A) Effect of salt and RNase treatment on retention of MSY2 in the Triton X-100 insoluble fraction. Triton X-100
insoluble fraction was prepared from oocytes and eggs and treated with increasing concentrations of KCl (left panel) for 10 min prior or RNase (right panel) for 15 min prior to
preparing the samples for immunoblot analysis. The experiment was performed 3 times and shown is a representative immunoblot. (B) The relative amount of MSY2 present in GV-
intact oocytes and MII eggs. Immunoblot analysis for MSY2 was performed on total oocyte and egg extracts and on the Triton X-100 insoluble material. Lane 1, Total amount of MSY2
in GV-intact oocyte; lane 2, amount of MSY2 in Triton X-100 insoluble material; lane 3, total amount of MSY2 in MII egg; lane 4, amount of MSY2 in Triton X-100 insoluble material in
MII egg. Note that themajority of MSY2 remains associated with the Triton X-100 insoluble material. The histogram shows a decrease in the amount of MSY2 in eggs relative to that in
GV-intact oocytes (ﬁrst bar), whereas the second and third bars depict the amount of MSY2 present in the insoluble fraction relative to the amount present in untreated oocytes and
MII eggs. The experiment was performed 3 times and the data are expressed as the mean±SEM. The difference between GV insoluble/total and MII insoluble/total is signiﬁcant
(pb0.05, Student's t-test). (C) Relative amount of different mRNAs present in the Triton X-100 insoluble fraction derived from oocytes (solid bars) and eggs (open bars). The
experiment was performed three times and the data are expressed as the mean±SEM. The differences between GV and MII are signiﬁcant (pb0.05) except for Hdac1, G6pdx, Khdrbs1,
Rbm8, Rad51ap1, Mlh3, and MuERV-L.
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To test the hypothesis that CDC2A could serve as the primary
trigger to induce mRNA degradation, Cdc2a mRNA was injected into
oocytes inhibited from undergoing spontaneous maturation in vitro
by the PDE3 inhibitor milrinone. Such injected oocytes underwent
GVBD as previously described (de Vantéry et al., 1997) and the extent
of both MSY2 phosphorylation and mRNA degradation was similar to
that observed during the course of normal maturation (Fig. 5B).
Likewise, induction of GVBD in meiotically incompetent oocytes
required injection of both Cdc2a and Ccnb1 mRNA as previously
described (de Vantéry et al., 1997) and inducedMSY2 phosphorylation
and mRNA degradation (data not shown).
To determine if continuous phosphorylation of MSY2 was required
for mRNA degradation, we established conditions inwhich roscovitine
was added immediately after GVBD, at which time MSY2 becomes
phosphorylated, and monitored the time course for dephosphoryla-tion. These experiments demonstrated that 60 μM roscovitine resulted
in conversion of phosphorylated MSY2 to the non-phosphorylated
form within 60 min (Fig. 5C insert). Examining degradation of a
selected sub-set of mRNAs in these treated oocytes revealed that the
Fig. 4. Effect of exogenous RNase onmRNA degradation in Triton X-100 preparations made from oocytes (solid bars) or MII eggs (open bars). The samples were incubated with RNase
(1 ng/ml) for 15 min at room temperature and then processed for qRT-PCR. The data are expressed relative to that in untreated samples. The experiment was performed 3 times and
the data are expressed as the mean±SEM. All differences are signiﬁcant (pb0.01).
210 S. Medvedev et al. / Developmental Biology 321 (2008) 205–215extent of degradation observed at times that corresponded to MI and
MII was less than that which occurred during maturation (Fig. 5C). In
addition, when oocytes were matured to MII, mRNA degradation
continued in the MII-arrested eggs that were cultured for an
additional 6 h (data not shown); virtually all of the MSY2 is
phosphorylated in MII-arrested eggs.
Dominant-negative forms of MSY2 inhibit and constitutively active forms
promote degradation of maternal mRNAs
The tight correlation between MSY2 phosphorylation and mRNA
degradation suggests MSY2 phosphorylation triggers the transition
from mRNA stability to mRNA instability, i.e., mRNA degradation. If a
causal relationship exists, non-phosphorylatable forms of MSY2
should inhibit the maturation-associated decrease in maternal
mRNAs, whereas constitutively active forms should lead to mRNA
degradation in the absence of maturation and CDC2A activation.
Prior to undertaking these studies, we ﬁrst needed to identify the
phosphorylated residues in MSY2. The limited amounts of material
that can be isolated, however, precluded using mass spectroscopy to
identify these sites. To circumvent this problem we focused on the
three potential phosphorylation sites T58, 67, and 78 and used in vitro
mutagenesis to convert these T residues to A residues. ThemRNA to be
injected was a MSY2 fused in frame to GFP. This permitted us to
resolve and quantify the exogenously expressed MSY2 from endo-
genousMSY2 using our afﬁnity-puriﬁedMSY2 antibody. Moreover, we
could ascertain whether the mutated forms underwent an electro-
phoretic shift diagnostic for phosphorylation.
As anticipated the non-mutated form displayed an electrophoretic
shift but the triple mutant did not (Fig. 6A). The T78A form exhibited a
shift similar to that for WT, whereas the T58A form displayed a smaller
shift, suggesting that both T58 and T67 are phosphorylated. The T67A
form, however, didn't manifest any apparent shift. Although this could
suggest that T67 phosphorylation is prerequisite for T58 phosphoryla-
tion, as described below, a putative constitutively active form T58D
didn't reveal an electrophoretic shift whereas the T67D form did (Fig.
6C). Thus, T58 phosphorylation may not lead to an electrophoretic shift.
Expression of the exogenous MSY2 dominant-negative forms
expanded the endogenous pool by ~26% as assessed by quantifying
the immunoblots. It should be noted that MSY2 is an abundant protein
in oocytes, constituting ~2% of total protein (Yu et al., 2001). Thus, a
modest expansion of the endogenous pool of MSY2 was expected and
consequently, any inhibitory effects of the putative dominant-
negative forms on mRNA degradation would not be anticipated tobe dramatic. In addition, themagnitude of any effect would depend on
the ability of the exogenously expressed MSY2 to be incorporated into
MSY2-containing RNPs. Consistent with MSY2 phosphorylation lead-
ing to a transition frommRNA stability to instability is the statistically
signiﬁcant effect of the mutant forms, and in particular the T67A form,
to inhibit the maturation-associated decrease in maternal mRNAs
relative to oocytes expressing the non-mutated form (Fig. 6B). The
effects of the individual mutant forms can be compared to each other
with a fair degree of conﬁdence because the overall level of expression
for each form was similar.
As anticipated, expressing putative constitutively active forms of
MSY2, in which the T residue was mutated to a D residue, in oocytes
inhibited from resuming meiosis by incubating them in the presence
of IBMX resulted in mRNA degradation (Fig. 6D). Again, because the
endogenous MSY2 pool was only moderately expanded (~42%) by
expressing the putative constitutively active forms of MSY2 (Fig. 6C),
the stimulatory effect was expected to be modest as was observed.
Moreover, the T67D form seemed more effective, consistent with the
T67A form often being a more potent inhibitor of maturation-
associated mRNA degradation. Last, expressing constitutively active
forms of MSY2 in oocytes also resulted in an increased susceptibility of
endogenous mRNAs to exogenous RNase treatment (Fig. 7).
When taken together, results of these experiments provide strong
evidence that MSY2 phosphorylation triggers the transition from
mRNA stability to instability that occurs shortly after GVBD.
The amount of MSY2 protein decreases during oocyte maturation
The amount of MSY2 decreases about 30% during maturation (Fig.
3B). This decrease could be a consequence of the maturation-
associated decrease in Msy2 mRNA (Fig. 5A). To test this hypothesis,
oocytes were injected with Msy2 dsRNA and incubated in medium
containing milrinone to inhibit maturation. After 18 h in culture, the
same amount of time used to determine the amount of MSY2
following maturation in vitro, the amount of MSY2 present relative
to the amount in uninjected oocytes was determined by immuno-
blotting. In addition the relative amount of Msy2 mRNA was
quantiﬁed by qRT-PCR. Results of these experiments, in which
MSY2 was not phosphorylated, indicated that 57%±2% (mean±SEM,
n=3) of the MSY2 protein and 21%±3% (mean±SEM, n=3) of the
Msy2 mRNA remained when compared to controls, i.e., there was
~40% and 80% reduction in the amount of protein and mRNA,
respectively. Thus, the maturation-associated decrease in MSY2
protein is likely due to the maturation-associated decrease in Msy2
Fig. 5.Maturation-associated decrease in degradation of speciﬁcmRNAs. (A) qRT-PCR analysis of relative abundance of randomly selected transcripts expressed in oocytes atMI (solid
bars) and MII (open bars) relative to the amount present in GV-intact oocytes. The experiment was performed three times and the data are expressed as the mean±SEM. For MI, all
differences are signiﬁcant (pb0.05, Student's t-test) except forMos, Tead2, and Rnf38, which are not. For MII, all differences are signiﬁcant (pb0.05). (B) Relative abundance of mRNAs
in milrinone-treated oocytes injected with Cdc2amRNA. qRT-PCR analysis was conducted at times that correspond to MI (solid bars) and MII (open bars) and the data are expressed
relative to the amount present in GV-intact oocytes; top panel control and bottom panel Cdc2amRNA-injected oocytes. The experiment was performed three times and the data are
expressed as themean±SEM. All differences in the control and experimental MI andMII groups are signiﬁcant (pb0.05) except for Rnf38 in MI andMII eggs, which is not. The insert is
an immunoblot of MSY2 in GV-intact oocytes (−) and oocytes injected with Cdc2amRNA (+) that underwent GVBD and demonstrates that MSY2 is phosphorylated in these oocytes.
(C) Continuous phosphorylation of MSY2 is required for degradation of most mRNAs. Roscovitine was added shortly after GVBD and relative amounts of the different mRNA were
determined at times that corresponded to MI (solid bars) and MII (open bars); top panel control and bottom panel roscovitine-treated oocytes. The experiment was performed three
times and the data are expressed as the mean±SEM. All differences in the control MI andMII groups are signiﬁcant (pb0.05, Student's t-test) except for Rnf38, which is not for MI. For
the roscotivine-treated group, the only differences that are signiﬁcant are for Rnf38 in MII and Rad51ap1 in both MI and MII. Under these conditions, MSY2 returns to the form of
greatest electrophoretic mobility within 60 min following roscovitine addition (Insert).
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amount of MSY2 protein and ~50% decrease in Msy2 mRNA that
occurs during maturation.
Discussion
Results described here provide the ﬁrst evidence that phosphor-
ylation of MSY2 constitutes a molecular switch in which non-phosphorylated MSY2 stabilizes maternal mRNAs whereas phosphor-
ylation of MSY2, as a consequence of CDC2A activation, triggers the
maturation-associated degradation of maternal mRNAs. Because
MSY2 is a germ cell-speciﬁc RNA-binding protein, MSY2 is ideally
suited to serve as such a switch to promote degradation of maternal
mRNAs. If an RNA-binding protein that is expressed in both oocytes
and somatic cells served as the switch, i.e., exhibited the proposed
change in function following CDC2A-mediated phosphorylation, most
Fig. 6. Effect of putative dominant-negative and constitutively active forms of MSY2 on degradation of maternal mRNAs. For dominant-negative forms, oocytes were injectedwith the
indicatedMsy2-Egfp-chimeric mRNAs and following incubation to allow expression, a fraction of the samplewas removed for both immunoblot and qRT-PCR analyses. The remainder
of the sample was matured in vitro and following maturation both immunoblotting and qRT-PCR analyses were performed. (A) Immunoblot analysis. Shown are the regions
containing the EGFP–MSY2 fusion protein and endogenous MSY2. (B) qRT-PCR analysis inwhich the amount of mRNA in MII eggs is expressed relative to that in the GV-intact oocyte.
Data are expressed as mean±SEM. a, pb0.05; b, pb0.01; c, pb0.001. In both cases, the experiment was performed three times and similar results were obtained in each case; shown
is a representative example for the immunoblotting analysis. For constitutively active forms, oocytes were injectedwith the indicated Egfp-chimeric mRNAs and following injection, a
fraction of the sample was removed for qRT-PCR analyses. The remainder of the sample cultured in vitro under conditions that inhibit maturation and following incubation both
immunoblotting and qRT-PCR analyses were performed. (C) Immunoblot analysis. Shown are the regions containing the EGFP–MSY2 fusion protein and endogenous MSY2. (D) qRT-
PCR analysis in which the amount of transcript in oocytes that had been microinjected is expressed relative to that in uninjected oocytes. Data are expressed as mean±SEM. a,
pb0.05; b, pb0.01; c, pb0.001.In both cases, the experiment was performed three times and similar results were obtained in each case; shown is a representative example for
the immunoblotting analysis.
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Fig. 7. Effect of putative constitutively active forms ofMSY2 on susceptibility of endogenousmRNAs to exogenously added RNase. Following injection and incubation under conditions
that inhibit maturation, the samples were extracted with Triton X-100 and either treated or not treated with RNase, and qRT-PCR was then performed. The data are expressed as the
amount of transcript in RNase-treated preparations relative to that in untreated ones. The experiment was performed three times and the data are expressed as mean±SEM. a,
pb0.05; b, pb0.01.
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during M-phase of each cell cycle. In fact, most mRNAs appear to
become more stable during M-phase (Ross, 1997), which may
represent the outcome of selective pressures to ensure that the
daughter cells inherit an essentially full complement of mRNAs. It
should be noted that mouse oocytes also express MSY4 (Davies et al.,
2000); a role for MSY4, if any, in the transition from maternal mRNA
stability to instability remains unknown.
Based on the time course for MSY2 phosphorylation and the ability
of roscovitine, but not U0126, to inhibit that phosphorylation, the
results of experiments described here suggest that CDC2A triggers
phosphorylation of MSY2, which contains consensus CDC2A phos-
phorylation sites. There are three consensus CDC2A phosphorylation
sites—recombinant CDC2A–CCNB1 stoichiometically converts MSY2
to the phosphorylated form in vitro (Medvedev, unpublished
observations)—and it is interesting that early in the course of
maturation we detect more than one form of slower electrophoretic
mobility. CDC2A would be an ideal candidate to initiate MSY2
phosphorylation, because it would ensure that nuclear and cytoplas-
mic maturation are coordinated, and thereby maximize the likelihood
of producing an egg capable of being fertilized and supporting
development to term. We cannot exclude, however, that MSY2 is
phosphorylated by a protein kinase that is activated by CDC2A. For
example, the Xenopus ortholog of MSY2, FRGY2 is phosphorylated by
casein kinase II (Deschamps et al., 1997), but there is no evidence that
CKII is activated by CDC2A during the course of oocyte maturation. In
mouse male germ cells, a kinase that co-immunoprecipitates with
MSY2 can phosphorylate MSY2 in vitro, but the kinase is not CKII
(Herbert and Hecht, 1999).
The Scansite algorithm identiﬁes an AKT phosphorylation site on
S139 of MSY using a low stringency ﬁlter. Recently, AKT was
implicated in phosphorylating the Y-box protein, YB-1 (Evdokimova
et al., 2006). Although AKT is activated during oocyte maturation, its
activation precedes CDC2A activation. Moreover, its activation is
transient and virtually no activity is detected shortly after GVBD
(Kalous et al., 2006). These ﬁndings minimize the likelihood that AKT
is the responsible kinase for MSY2 phosphorylation. Of interest,
however, is that YB-1 preferentially interacts with the 5′ cap and
displaces the cap-binding protein eIF-4A that is essential for
translation (Evdokimova et al., 2006). In addition, AKT-mediated
phosphorylation of YB-1 on S102, e.g., in response to IGF1 stimulation,
decreases the ability of YB-1 to interact with the 5′ cap and displace
eIF-4A; the Scansite algorithm detects this site using a low stringency
ﬁlter. Thus, AKT-mediated phosphorylation of YB-1 could promoterelief of translational repression of mRNAs in YB-1 containing RNPs. It
is tempting to speculate that MSY2 phosphorylation leads to similar
changes that could ultimately lead to decreased mRNA stability that is
coupled to translation.
We noted a tight correlation between MSY2 phosphorylation and
mRNA degradation and that mRNA degradation required continuous
phosphorylation of MSY2. The spectrum of differences in the temporal
pattern of degradation of speciﬁc mRNAs likely reﬂects another level
of regulation beyond a function for MSY2. Thus, if MSY2 confers mRNA
stability and phosphorylation relieves that protection, the stability of
each mRNA may then be dictated by combination of regulatory
sequences in that mRNA and the protein composition of the MSY2-
containing RNP. At present, we have no information regarding the
composition of MSY2-containing RNPs in mouse oocytes.
Following the transition from mRNA stability to instability, the
machinery responsible for degradation of maternal mRNAs has not
been described in mouse. In zebraﬁsh a single miRNA (Mir-430) that is
expressed when the embryonic genome is activated and responsible
for targeting degrading of several hundred maternal mRNAs (Giraldez
et al., 2006). In mouse the bulk of maternal mRNAs appear degraded
prior to genome activation. Of those maternal mRNAs degraded
during maturation, only a small fraction contained seed sequences for
miRNAs (Murchison et al., 2007) suggesting that miRNAs do not
constitute the major pathway for clearing maternal mRNAs. Rather a
large fraction of the degraded maternal mRNAs were enriched in AU-
rich elements and sequences derived from repetitive elements. The
presence of repetitive element-derived sequences could target these
mRNAs by an RNAi pathway using siRNAs derived from repetitive
sequences. In Drosophila the CCR4/POP2/NOT deadenylase catalyzes
the ﬁrst steps in degradation of maternal mRNAs (Semotok et al.,
2005). The role of this deadenylase, or that of either decapping
enzyme DCP2 or the 5′-exonuclease XRN1 (Eulalio et al., 2007), in
degradation of maternal mouse mRNAs is not known.
In GV-intact oocytes N80% of the mRNAs analyzed are present in
insoluble material following Triton X-100 extraction. This ﬁnding could
account for the observed mRNA stability during oocyte growth, because
mRNAs present in this compartment may not be translated and hence
less susceptible to degradation. In addition, these mRNAs may also be
shielded from the RNA degradationmachinery. Messenger RNAs present
in the soluble fraction would provide the source of transcripts that
support protein synthesis during oocyte growth; these transcripts would
be in a dynamic equilibrium with their counterparts in the insoluble
fraction. Phosphorylation changes the biochemical properties of MSY2,
e.g., it is released from the insoluble fraction at lower salt concentrations
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MSY2 could also underlie the dramatic increase in susceptibility of
endogenous mRNAs to exogenous RNase in MII eggs, suggesting that
phosphorylation of MSY2 increases accessibility of mRNAs present in
RNPs to enzymes involved in mRNA degradation.
The most compelling case for a direct linkage that MSY2
phosphorylation triggers the transition from mRNA stability to
instability is that expressing putative dominant-negative forms of
MSY2 inhibits the maturation-associated decrease in endogenous
mRNAs, whereas expressing putative constitutively active forms
results in a decrease in these mRNAs in the absence of maturation.
Consistent with the increased susceptibility of endogenous mRNAs in
MII eggs, in which MSY2 is phosphorylated, to exogenous RNase is the
observation that expressing putative constitutively active forms of
MSY2 in oocytes also increases the susceptibility of endogenous
mRNAs to exogenous RNase. This ﬁnding is consistent with the
increased sensitivity of endogenous mRNAs to degradation by
exogenously added RNase in MII eggs in which the bulk of MSY2 is
phosphorylated when compared to their GV-intact counterparts.
Selex analysis reveals that FRGY2 exhibits preferential binding for
AACAUC sequence (Bouvet et al., 1995) and a similar sequence has
been determined for MSY2 (Hecht, unpublished results). In male germ
cells MSY2 preferentially associates with a population of mRNAs (Yang
et al., 2005a). MSY2 can also serve as a transcription factor, and ChIP
assays revealed that most mRNAs that preferentially bind MSY2 are
transcribed from genes that contain a Y-box DNA-binding in their
promoters (Yang et al., 2005a). Whether MSY2 preferentially binds to
a sub-population of mRNAs in oocytes is not known. Analysis of
microarray data of transcript abundance of oocyte-speciﬁc mRNAs
during oocyte maturation and early embryogenesis reveals waves of
degradation of these mRNAs with some being degraded by MII, and
others being degraded following fertilization or after the 2-cell stage
(P. Svoboda, personnel communication). How these mRNAs evade
being degraded during maturation is not known (nor what promotes
their degradation at later times); it will be of great interest to ascertain
whether MSY2 is bound to them or not.
We propose that MSY2 is a major factor responsible for mRNA
stability during oocyte growth and that its phosphorylation, which
initiates at the onset of oocyte maturation and is mediated by CDC2A,
results in a transition from a state of mRNA stability to mRNA
instability. Maturation is also associated with a decrease in the
amount of MSY2 protein, with the decrease in Msy2 mRNA likely
contributing to this decrease. This ﬁnding suggests a positive-
feedback loop in which MSY2 phosphorylation leads to degradation
of Msy2 mRNA (among many mRNAs) that in turn leads to a decrease
in MSY2 protein, the net effect being a further decrease in global
mRNA stability that is triggered by CDC2A-mediated phosphorylation
of MSY2. The ability to inhibit mRNA degradation by over-expressing
dominant-negative MSY2 permits an experimental approach to assess
the requirement for degradation of maternal mRNAs in the maternal-
to-zygotic transition inmouse.Whether a similar role forMSY2 and its
phosphorylation in the transition from mRNA stability to instability
exists in other mammals remains to be determined.
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